SEC Form 4 · accession 0001179110-17-002204
Assertio Therapeutics, Inc · ASRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James A Schoeneck
Officer — President and CEO · Director
Period of report
Feb 8, 2017
Accepted (ET)
Feb 10, 2017 · 7:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001005201
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Feb 8, 2017 | A | 105,000 | A | — | — | Common Stock | 105,000 | 105,000 | D |
| Stock OptionsF3 | $17.09 | Feb 8, 2017 | A | 245,000 | A | — | Feb 8, 2027 | Common Stock | 245,000 | 245,000 | D |
Explanation of responses
- F1Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit.
- F2These restricted stock units are scheduled to vest 25% on December 1, 2017, 25% on December 1, 2018, 25% on December 1, 2019, and 25% on December 1, 2020, assuming continued employment through the applicable vesting date.
- F3These stock options are exercisable in 48 equal monthly installments.